01—Abstract
Summary
Summary of the 8-K filed October 6, 2026. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics Incorporated (DGX) has announced a significant leadership transition involving Catherine T.
Doherty, who will retire in July 2027. To ensure a smooth handover and leverage her expertise, Ms. Doherty will transition from her current role to Executive Vice President, effective November 1, 2026. In this new capacity, she will focus on key strategic areas including health systems, the company's joint venture with Corewell Health, and Project Nova, a critical initiative aimed at modernizing the "Order to Cash" business processes and associated IT infrastructure.
This transition is accompanied by adjustments to Ms. Doherty's compensation and incentive structure. Her base salary of $650,000a and target annual incentive compensation remain unchanged. However, she will receive a long-term equity award valued at $1,200,000, entirely in restricted stock units, granted on November 3, 2026.
This award aligns with the terms of other senior executive long-term incentives. Investors should note that this filing does not involve any new financial performance disclosures or material changes in business operations beyond this executive transition.
02—Key points
Key Highlights
- Catherine T. Doherty to transition to Executive Vice President role effective November 1, 2026, preceding her retirement in July 2027.
- Ms. Doherty's new responsibilities will include health systems, the Corewell Health joint venture, and Project Nova (Order to Cash process modernization).
- Base salary of $650,000 remains unchanged for Ms. Doherty.
- Annual incentive compensation target of 80% of base salary remains unchanged.
- Approved equity award of $1,200,000, allocated 100% to restricted stock units, with a grant date of November 3, 2026.
- Equity award terms are substantially similar to those granted to other senior executives in 2026.
- This filing primarily concerns an executive transition and does not include new financial results or operational updates.
03—Questions
Frequently Asked Questions
What is the significance of Catherine T. Doherty's transition and impending retirement?
Catherine T. Doherty's transition to Executive Vice President is significant because it allows Quest Diagnostics to retain her expertise in crucial strategic areas like health systems, a key joint venture, and a major business process modernization project (Project Nova) during the period leading up to her retirement in July 2027. This ensures continuity and strategic focus in these important initiatives.
How will Ms. Doherty's compensation be affected by this role change?
Ms. Doherty's annual base salary of $650,000 and her target annual incentive compensation (80% of base salary) will remain unchanged. She will, however, receive a new long-term equity award valued at $1,200,000, comprised entirely of restricted stock units, which is consistent with awards given to other senior executives.
What is 'Project Nova' and why is it important?
Project Nova is described as a multi-year initiative by Quest Diagnostics to modernize its 'Order to Cash' business processes. This includes updating the associated information technology infrastructure and underlying technologies. Modernizing these core operational processes is crucial for improving efficiency, customer experience, and financial reporting accuracy.
Does this 8-K filing contain any new financial performance information for Quest Diagnostics?
No, this 8-K filing, specifically Item 5.02, focuses solely on the departure and appointment of certain officers, detailing the transition of Catherine T. Doherty. It does not provide any new financial results, revenue figures, or operational performance metrics for Quest Diagnostics.
04—Continue